Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Link

Showing results (21-30 of 48) with videos related to

Pageof 5
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 20, 2023
Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancerMatti S Aapro, Stephen Chaplin, Paul Cornes, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 17, 2018
Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factorsCamille N Abboud, Nicole Lang, Henry Fung, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 18, 2020
Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia studyHartmut Link, G Illerhaus, U M Martens, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 27, 2017
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendationsMatti Aapro, Ralph Boccia, Robert Leonard, et al.
Journal of Clinical Medicine|March 28, 2026
German Expert Consensus on Opioid-Induced Constipation (OIC): Recommendations and a Treatment Algorithm for Clinical PracticeBastian Wobbe, Viola Andresen, Ralf Baron, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2026
Evidence-based AGIHO guideline update on prophylaxis of infectious complications with granulocyte-stimulating factors (G-CSF) for the treatment of adult patients with cancerMichael Sandherr, Enrico Schalk, Werner J Heinz, et al.
British Journal of Haematology|February 26, 2013
Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemiaBrigitte Mohr, Johannes Schetelig, Kerstin Schäfer-Eckart, et al.
Wiener Klinische Wochenschrift|September 17, 2015
Iron metabolism and iron supplementation in cancer patientsHeinz Ludwig, Rayko Evstatiev, Gabriela Kornek, et al.
British Journal of Haematology|December 30, 2014
Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre studySebastian Kirschey, Thomas Flohr, Hans H Wolf, et al.
European Radiology|August 17, 2022
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306Felix O Hofmann, Volker Heinemann, Melvin D'Anastasi, et al.
Pageof 5

Showing results (21-30 of 48) with videos related to

Sort By:
Pageof 5
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 20, 2023
Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancerMatti S Aapro, Stephen Chaplin, Paul Cornes, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 17, 2018
Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factorsCamille N Abboud, Nicole Lang, Henry Fung, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 18, 2020
Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia studyHartmut Link, G Illerhaus, U M Martens, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 27, 2017
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendationsMatti Aapro, Ralph Boccia, Robert Leonard, et al.
Journal of Clinical Medicine|March 28, 2026
German Expert Consensus on Opioid-Induced Constipation (OIC): Recommendations and a Treatment Algorithm for Clinical PracticeBastian Wobbe, Viola Andresen, Ralf Baron, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2026
Evidence-based AGIHO guideline update on prophylaxis of infectious complications with granulocyte-stimulating factors (G-CSF) for the treatment of adult patients with cancerMichael Sandherr, Enrico Schalk, Werner J Heinz, et al.
British Journal of Haematology|February 26, 2013
Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemiaBrigitte Mohr, Johannes Schetelig, Kerstin Schäfer-Eckart, et al.
Wiener Klinische Wochenschrift|September 17, 2015
Iron metabolism and iron supplementation in cancer patientsHeinz Ludwig, Rayko Evstatiev, Gabriela Kornek, et al.
British Journal of Haematology|December 30, 2014
Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre studySebastian Kirschey, Thomas Flohr, Hans H Wolf, et al.
European Radiology|August 17, 2022
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306Felix O Hofmann, Volker Heinemann, Melvin D'Anastasi, et al.
Pageof 5